<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Neuroscience</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F4BBE50D-F07C-432F-A461-F0EE2EA2CF85"><gtr:id>F4BBE50D-F07C-432F-A461-F0EE2EA2CF85</gtr:id><gtr:firstName>(Aaron)</gtr:firstName><gtr:otherNames>Tsu</gtr:otherNames><gtr:surname>Chuang</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F74A7E46-F1D9-421A-BF10-4EFDAD81DFE7"><gtr:id>F74A7E46-F1D9-421A-BF10-4EFDAD81DFE7</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Killick</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FBF7F4F1-2D70-48F8-B1A1-40980172983B"><gtr:id>FBF7F4F1-2D70-48F8-B1A1-40980172983B</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:otherNames>N</gtr:otherNames><gtr:surname>Hopkins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1AD81458-D7F1-4E1D-9D49-DA319E1C5D6C"><gtr:id>1AD81458-D7F1-4E1D-9D49-DA319E1C5D6C</gtr:id><gtr:firstName>Diane</gtr:firstName><gtr:surname>Hanger</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0700653"><gtr:id>F2097C05-FFFD-4A92-9CC4-D9D1662111C1</gtr:id><gtr:title>Mechanisms underlying the differential response to rosiglitazone of individuals with different ApoE genotypes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700653</gtr:grantReference><gtr:abstractText>Alzheimer?s disease (AD) is a very complex disorder for which there are few known risk factors. However it is known that advancing age increases the risk of developing AD as does possession of a particular type of a protein called apolipoprotein E (ApoE). ApoE occurs in three types (ApoE2, ApoE3, ApoE4) and possession of ApoE4 is associated with an increased risk of developing AD.

One of the primary characteristic features of AD is the presence in the brain of clumps of a protein called amyloid beta-peptide (Abeta), the presence of which is thought to be detrimental to nerve cells. Abeta derives from a larger protein, called amyloid precursor protein (APP), from which Abeta is cut out. Cleavage of APP occurs primarily in the membranes of nerve cells, but in specific regions called ?lipid rafts? from where it is then exported to the outside of the cell to form the detrimental clumps containing Abeta.

A drug that is used to treat diabetes (Avandia?), developed by GlaxoSmithKline, has recently been found to be useful for treating some people with AD. However, Avandia? was only beneficial for people carrying ApoE3 or ApoE2 and not ApoE4. The main functions of ApoE are to bind lipids and cholesterol and to transport them around the body. The different types of ApoE perform these functions with differing abilities but it is not known how this might relate to the differences in the observed therapeutic effects of Avandia? in AD sufferers. It is important therefore to try to understand how Avandia? is working so that better drugs can be developed.

Our hypothesis is that the differential effects of Avandia? in AD patients may be related to differences in the ApoE forms that result in different (1) ability to remove Abeta from the brain or (2) sensitivity of nerve cells to the toxic effects of Abeta.

Results that are of interest to the general public will be publicised on the MRC Centre for Neurodegeneration website and through reports in the associated bulletins as well as through press reports where appropriate.</gtr:abstractText><gtr:technicalSummary>A recent study of the effects of rosiglitazone (Avandia?), a thiazolidinedione (TZD) anti-diabetic drug, in people with Alzheimer?s disease (AD) has revealed differential effects that are dependent on the apolipoprotein E (ApoE) status of individuals. ApoE4 genotype is associated with increased risk of developing AD but non-ApoE4 carriers responded positively to rosiglitazone, whereas patients harbouring ApoE4 alleles did not show improvement in symptoms. 

The aim of this study is to investigate the mechanism of action of rosiglitazone and the relationship to generation of neurotoxic amyloid-beta peptide (Abeta) in different ApoE backgrounds. These experiments will investigate whether (1) rosiglitazone modifies the protein composition of lipoproteins differentially according to ApoE genotype ? this would then lead to modulation of Abeta toxicity and/or (2) Abeta generation also exhibits ApoE isoform-specific differences that are further amplified by rosiglitazone.

The proposed research plan will use astrocytic cultures expressing different ApoE isoforms to explore the possibility that ApoE influences the protein composition of ApoE-containing lipoprotein particles. In parallel studies we will examine the effects of rosiglitazone on the generation of neurotoxic Abeta, the major component of amyloid plaques in AD brain, in the lipid rafts of neurons with differing ApoE genotypes. ApoE could thus function as a regulator of protein composition, and hence function, of lipid rafts and this may account for the observed differential, ApoE genotype-dependent, susceptibility to AD based on differences in Abeta production.

The results of this study should result in identification of novel targets for AD and development of new TZDs for which patient response is not ApoE isoform selective.</gtr:technicalSummary><gtr:fund><gtr:end>2012-06-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>429993</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Neurology and GI Centre of Excellence for Drug Discovery (CEDD) GSK</gtr:department><gtr:description>GSK</gtr:description><gtr:id>29C9E43E-C152-437B-9A1C-A0891CDDD492</gtr:id><gtr:impact>Multidisciplinary collaboration (cell biology, animal models, molecular biology, biochemistry, mass spectrometry)</gtr:impact><gtr:partnerContribution>GSK contributed transgenic animals and relevant expertise at the outset of the project</gtr:partnerContribution><gtr:piContribution>Methodology to generate astrocyte cultures, obtain medium and enrich for apolipoproteins.
Mass spectrometric analysis</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>87FA31C8-9041-4ADF-ACAF-3FF8E67FC079</gtr:id><gtr:impact>Tours of the facilities and subsequent discussions with members of the public

Local interest is high</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Open day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9927E5F4-FAAE-4D1B-9F4C-746888C5B99E</gtr:id><gtr:impact>Description of ongoing laboratory research

None known</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E1A7CB0D-664F-43DE-8405-08050019291A</gtr:id><gtr:impact>Presentations to members of the public at the MRC Centre for Neurodegeneration Open Day, King's College London

Presentation of information</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6CB35DAB-B04C-445E-B19B-2EF7C73EDEC0</gtr:id><gtr:impact>Demonstrations at MRC Centre for Neurodegeneration Research Open Day

Not known</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Year 12 mock interviews</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F4CF425A-32B2-4E49-9317-54A300CF2EC6</gtr:id><gtr:impact>Year 12 school students underwent formal mock interviews

School reports that this is very useful for students preparing for university and for taking up employment after leaving school</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011,2012,2013,2014,2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC CASE AstraZeneca Studentship</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>05CB2E61-AC6B-4216-A3BC-8A8C8AFDF0BC</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>98000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>King's Overseas Research Studentship</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>King's College London (KCL)</gtr:fundingOrg><gtr:id>4745FBA8-3548-4B81-8E83-E7B44E7D23C8</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>103000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC/Lilly CASE Studentship</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>661F07F9-8E88-4C65-9D6A-6397C432DA31</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NIHR workshop on dementia research</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>468E7509-27F2-495E-AD1C-F44C66C83554</gtr:id><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Dementia Research Portal Working Group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FF6317CC-D4AD-42B1-96A3-75A0B1BBBABE</gtr:id><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Identification of lipoproteins secreted by astrocytes</gtr:description><gtr:id>2B101D55-4131-47F2-AFB3-9D1AF0B9F9D5</gtr:id><gtr:impact>N/A</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Astrocyte secreted lipoproteins</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FE532F5E-0FB3-4195-A0E5-81946F17BFE2"><gtr:id>FE532F5E-0FB3-4195-A0E5-81946F17BFE2</gtr:id><gtr:title>Astrocytes are important mediators of A?-induced neurotoxicity and tau phosphorylation in primary culture.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6c58c64d02a3edc3d0ae27f66455b7e2"><gtr:id>6c58c64d02a3edc3d0ae27f66455b7e2</gtr:id><gtr:otherNames>Garwood CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6E575DBC-5383-44A8-949F-70184E83D40D"><gtr:id>6E575DBC-5383-44A8-949F-70184E83D40D</gtr:id><gtr:title>Protocol for quantitative proteomics of cellular membranes and membrane rafts.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0ea2b4141de2b0b21acbe1f462237306"><gtr:id>0ea2b4141de2b0b21acbe1f462237306</gtr:id><gtr:otherNames>Thompson AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700653</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>